Article ID Journal Published Year Pages File Type
8733677 Critical Reviews in Oncology/Hematology 2018 24 Pages PDF
Abstract
The statistical methodology used to evaluate surrogate endpoints requires consistency in order to facilitate the accurate interpretation of the results. Despite the limited number of clinical settings with validated surrogate endpoints for OS, there is evidence of good surrogacy for DFS and PFS in tumor types that account for a large proportion of cancer cases.
Related Topics
Health Sciences Medicine and Dentistry Hematology
Authors
, , , , , , , ,